Maccura Biotechnology Co.Ltd (SHE:300463)
China · Delayed Price · Currency is CNY 9.45
+0.03 (0.32%)
Aug 11, 2026, 3:04 PM CST
SHE:300463 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,117 | 2,151 | 2,525 | 2,862 | 3,568 | 3,934 |
Other Revenue | 12.34 | 19.24 | 23.39 | 33.95 | 40.18 | 46.47 |
| 2,129 | 2,170 | 2,549 | 2,896 | 3,608 | 3,981 | |
Revenue Growth | -9.19% | -14.84% | -11.98% | -19.75% | -9.35% | 7.47% |
Cost of Revenue | 949.07 | 958 | 1,195 | 1,384 | 1,712 | 1,740 |
Gross Profit | 1,180 | 1,212 | 1,354 | 1,512 | 1,897 | 2,240 |
Selling, General & Admin | 882.29 | 859.58 | 768 | 805.79 | 749.75 | 756.1 |
Research & Development | 307.48 | 317.94 | 323.15 | 324.17 | 273.22 | 207.27 |
Other Operating Expenses | 13.57 | 16.35 | 10.65 | 11.73 | 22.02 | 28.77 |
Operating Expenses | 1,243 | 1,225 | 1,092 | 1,180 | 1,081 | 999.91 |
Operating Income | -62.75 | -12.71 | 262.16 | 331.6 | 815.54 | 1,240 |
Interest Expense | -24.17 | -21.54 | -22.12 | -33.53 | -35.06 | -59.27 |
Interest & Investment Income | 8.74 | 6.86 | 9.33 | 18.62 | 24.15 | 5.4 |
Currency Exchange Gain (Loss) | -15.15 | -3.98 | 0.16 | 1.11 | 5.33 | -2.19 |
Other Non Operating Income (Expenses) | 10.26 | -10.55 | -5.52 | -6.21 | 3.2 | -3 |
EBT Excluding Unusual Items | -83.08 | -41.92 | 244 | 311.59 | 813.17 | 1,181 |
Impairment of Goodwill | - | - | -94.11 | - | - | - |
Gain (Loss) on Sale of Investments | -1 | -12.29 | 2.15 | -7.08 | -9.1 | - |
Gain (Loss) on Sale of Assets | -2.4 | -2.31 | -6.73 | -4.17 | -4.12 | -4.05 |
Asset Writedown | -30.9 | -47.25 | -36.54 | -9.54 | -22.46 | -26.01 |
Other Unusual Items | 6.5 | 4.24 | 15.88 | 14.56 | 11.59 | 35.81 |
Pretax Income | -110.88 | -99.54 | 124.65 | 305.37 | 789.08 | 1,187 |
Income Tax Expense | -62.46 | -58.04 | 5.89 | 0.69 | 87.38 | 184.88 |
Earnings From Continuing Operations | -48.42 | -41.49 | 118.76 | 304.68 | 701.71 | 1,002 |
Minority Interest in Earnings | 12.81 | 5.67 | 8.04 | 7.94 | 6.48 | -45.64 |
Net Income | -35.61 | -35.83 | 126.81 | 312.62 | 708.18 | 956.6 |
Net Income to Common | -35.61 | -35.83 | 126.81 | 312.62 | 708.18 | 956.6 |
Net Income Growth | - | - | -59.44% | -55.86% | -25.97% | 20.49% |
Shares Outstanding (Basic) | 600 | 604 | 606 | 609 | 604 | 553 |
Shares Outstanding (Diluted) | 600 | 604 | 613 | 612 | 608 | 557 |
Shares Change | -1.42% | -1.38% | 0.01% | 0.77% | 9.16% | -0.11% |
EPS (Basic) | -0.06 | -0.06 | 0.21 | 0.51 | 1.17 | 1.73 |
EPS (Diluted) | -0.06 | -0.06 | 0.21 | 0.51 | 1.17 | 1.72 |
EPS Growth | - | - | -59.44% | -56.19% | -32.18% | 20.62% |
Free Cash Flow | 75.02 | -146.74 | -329.22 | 23.61 | -144.52 | 1,015 |
Free Cash Flow Per Share | 0.13 | -0.24 | -0.54 | 0.04 | -0.24 | 1.82 |
Dividend Per Share | - | - | 0.104 | 0.154 | 0.349 | 0.471 |
Dividend Growth | - | - | -32.48% | -55.89% | -25.86% | 9.30% |
Gross Margin | 55.43% | 55.86% | 53.13% | 52.20% | 52.57% | 56.28% |
Operating Margin | -2.95% | -0.59% | 10.29% | 11.45% | 22.60% | 31.16% |
Profit Margin | -1.67% | -1.65% | 4.98% | 10.80% | 19.63% | 24.03% |
Free Cash Flow Margin | 3.52% | -6.76% | -12.92% | 0.81% | -4.00% | 25.50% |
EBITDA | 351.72 | 341.17 | 584.39 | 626.55 | 1,068 | 1,463 |
EBITDA Margin | 16.52% | 15.72% | 22.93% | 21.64% | 29.60% | 36.75% |
D&A For EBITDA | 414.46 | 353.88 | 322.23 | 294.94 | 252.56 | 222.54 |
EBIT | -62.75 | -12.71 | 262.16 | 331.6 | 815.54 | 1,240 |
EBIT Margin | -2.95% | -0.59% | 10.29% | 11.45% | 22.60% | 31.16% |
Effective Tax Rate | - | - | 4.72% | 0.23% | 11.07% | 15.57% |
Revenue as Reported | 2,129 | 2,170 | 2,549 | 2,896 | 3,608 | 3,981 |
Advertising Expenses | - | - | - | 104.69 | 96.23 | 114.73 |